ArticleCurrent opinion in biomedical engineering2026
Engineering Lymphatic Vessels and Lymphoid Microenvironments In Vitro to Investigate Immune Cell Trafficking.
Article in Current opinion in biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The lymphatic system is central to immune surveillance, coordinating antigen transport, and immune cell trafficking. While in vivo studies have revealed key aspects of lymphatic and lymph node biology, their complexity has motivated the development of in vitro platforms that enable controlled interrogation of specific immune processes. This review presents a tiered framework for organizing engineered lymphatic and lymph node models based on increasing architectural and functional complexity. Tier 1 models employ two-dimensional lymphatic endothelial monolayers to investigate immune cell docking, chemokine presentation, and junctional regulation. Tier 2 systems incorporate three-dimensional matrices and stromal organization to recreate lymphoid microenvironments, including lymph node scaffolds and immune organoids that support lymphocyte positioning and antigen handling under static conditions. Tier 3 platforms integrate microfluidic perfusion and compartmentalization to model lymphatic transport, flow-dependent endothelial behavior, and immune trafficking in dynamic lymphatic systems. Collectively, these models define the experimental landscape of in vitro lymphatic immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.